As of April 2011, many cuts to healthcare spending are being proposed and expected.
Health Canada has approved Fluad, a seasonal flu vaccine manufactured by Novartis for adults aged 65 years and older. Fluad is the first seasonal flu vaccine in Canada to contain an adjuvant.
The House Judiciary Committee is working to pass medical tort reform legislation.
Researchers in Japan have found that one inhaled dose of Daiichi Sankyo Co.Ltd.’s CS8958 (or laninamivir) worked better than Tamiflu to keep mice alive when infected with a normally deadly dose of H5N1 avian influenza.
The U.S. Food and Drug Administration (FDA) has approved Benlysta (belimumab) to treat patients with active autoantibody positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives and non steroidal anti-inflammatory drugs.
A recent study published revealed that pay-forperformance programs are effective in incentivizing low-performing physicians.
The number of annual flu deaths ,consistently reported to be 36,000 by the U.S. Centers for Disease Control and Prevention, has been revised.
Prolastin-C has been approved by the Food and Drug Administration for the treatment of alpha1-antitrypsin (AAT)deficiency.
A new study shows that lower levels of serum albumin are associated with greater disease severity in multiple myeloma patients.
Updates on vaccines including herpes, hepatitis E, dengue fever, cervical cancer and more.
Updates on recent FDA approvals, appointments, acquisitions and alliances in the pharmaceutical industry.
The Kaiser Family Foundation has launched an online gateway providing access to new and comprehensive resources on the health reform law.